Expertise in
3
conditions

Olivier Collard

Saint-etienne-de-valoux, FR 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
3
conditions
Saint-etienne-de-valoux, FR 

Overview

Olivier Collard practices practicing medicine in Saint-etienne-de-valoux, France.

Mr. Collard is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Angiosarcoma, Vaginal Cancer, and Pancreaticoduodenectomy.

He is actively involved in clinical research, co-authoring 65 peer reviewed articles and participating in 19 clinical trials.

Gender

Male

Locations

Saint-etienne-de-valoux, France
Other Locations
Saint-priest-la-vetre, France
Hôpital Cochin Port Royal
Vandoeuvre-les-nancy, France
Lyon, France
Irles, France
St Priest En Jarez, Sete, France
108 Bis Avenue Albert Raimond, Albert, 42270, France
Saint-etienne, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Enrollment Status: Recruiting
Publish Date: July 29, 2026
Intervention Type: Drug, Combination product
Study Drugs: Nilotinib, Everolimus, Sorafenib, Lapatinib, Pazopanib, Olaparib, Durvalumab, Tremelimumab
Study Phase: Phase 2
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Enrollment Status: Recruiting
Publish Date: June 24, 2026
Intervention Type: Genetic
Cohort Study to Evaluate the Clinical Features of Patients With Epithelial Ovarian Cancer Depending on Tumoral Mutation of BRCA or Beyond BRCA Genomic Molecular Abnormalities
Cohort Study to Evaluate the Clinical Features of Patients With Epithelial Ovarian Cancer Depending on Tumoral Mutation of BRCA or Beyond BRCA Genomic Molecular Abnormalities
Enrollment Status: Completed
Publish Date: June 08, 2026
A National, Multicenter, Randomized Controlled Trial to Assess the Efficacy of a Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Women With Metastatic Breast Cancer
A National, Multicenter, Randomized Controlled Trial to Assess the Efficacy of a Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Women With Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: May 04, 2026
Intervention Type: Device
Study Phase: Not Applicable
Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
Enrollment Status: Completed
Publish Date: March 18, 2026
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Multicenter, Randomized, Open-label, Phase II Trial Aiming to Evaluate the Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2 Positive Breast Cancer Patients
A Multicenter, Randomized, Open-label, Phase II Trial Aiming to Evaluate the Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2 Positive Breast Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: November 26, 2025
Intervention Type: Drug
Study Drugs: Trastuzumab, Paclitaxel, Pegfilgrastim
Study Phase: Phase 2
Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial
Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug
Study Drugs: Bevacizumab, Atezolizumab, Chemotherapy
Study Phase: Phase 3
Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy
Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2024
Intervention Type: Drug
Study Drugs: OSE2101, Pembrolizumab [Keytruda]
Study Phase: Phase 2
RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.
RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.
Enrollment Status: Unknown
Publish Date: August 26, 2024
Intervention Type: Genetic
Study Phase: Not Applicable
View 8 Less Clinical Trials

65 Total Publications

Corrigendum to "Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)": [Ann Oncol 26 (2015) 2168-2173].
Corrigendum to "Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)": [Ann Oncol 26 (2015) 2168-2173].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 16, 2025

Frequently Asked Questions about Olivier Collard

Is Olivier Collard a top-rated expert for Adult Soft Tissue Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Olivier Collard is classified as an Distinguished expert for Adult Soft Tissue Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Olivier Collard participate in research or clinical trials?

Yes. Olivier Collard has published 65 articles and abstracts on conditions like Adult Soft Tissue Sarcoma. You can view a list of Olivier Collard's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Collard's expertise for a condition
ConditionClose
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile